Extracellular Cyclic Nucleotides*

Broadus, Arthur E.; Hardman, Joel G.; Kaminsky, Neil I.; Ball, John H.; Sutherland, Earl W.; Liddle, Grant W.

doi:10.1111/j.1749-6632.1971.tb45235.x

Cited by 105 publications

(33 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…cAMP, cGMP, and beef heart 3',5'-cyclic nucleotide phosphodiesterase were purchased that concentration differences between the vessels could not be accounted for by different rates of metabolism. These rates of degradation are comparable to those found in human plasma (1) and much lower than those described for rat plasma (11). It can be calculated that even at the most rapid rate of degradation observed, less than 20% of the cyclic nucleotide in the sample would be destroyed before deproteinization with TCA.…”

Section: Methodsmentioning

confidence: 47%

Sources of Cyclic Nucleotides in Plasma

Wehmann¹,

Blonde²,

Steiner³

1974

J. Clin. Invest.

View full text Add to dashboard Cite

A B S T R A C T In order to determine the sites of net production and removal of the cyclic nucleotides in plasma, various blood vessels were catheterized in 17 anesthetized dogs and arterial and venous concentrations of adenosine 3',5'-monophosphate (cAMP) and guanosine 3',5'-monophosphate (cGMTP) were measured by radioimmunoassay.Aortic cAMP was 30±2 nM (mean±SE) and cGMP was 13+1 nM. There were no significant differences for either cyclic nucleotide between the concentration in the aorta and that in the inferior vena cava, coronary sinus, hepatic vein, and femoral vein. The concentration of cAMP in renal venous plasma was 25% lower than in aortic plasma, and renal venous cGMP was 51% lower than in the aorta. The pulmonary arterial concentrations of cAMP and cGMP were slightly lower than in the aorta. The concentration of cGMP in the superior mesenteric vein plasma was 83% greater than in aortic plasma; the concentration of cAMP in this vessel was only 16% greater than that in the aorta. Superior vena cava concentrations of both cyclic nucleotides were slightly greater than arterial concentrations.The results suggest that: (a) the kidneys are a major site of removal of both cyclic nucleotides from plasma. (b) The lungs may be a site of net addition of both cyclic nucleotides to plasma. (c) The small in-

show abstract

Section: Methodsmentioning

confidence: 47%

Sources of Cyclic Nucleotides in Plasma

Wehmann¹,

Blonde²,

Steiner³

1974

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…Plasma concentration of cyclic AMP is thought to originate as leakage of intracellular cyclic AMP into the extracellular space (Broadus et al, 1970(Broadus et al, , 1971. The level of cyclic AMP in plasma is only 1% of that in tissues (Karlberg et al, 1974) and although 13-adrenoceptor agonists are known in vitro to increase cyclic AMP levels in lung tissue, it is difficult to relate changes in plasma cyclic AMP to increases of cAMP within the bronchial smooth muscle.…”

Section: Discussionmentioning

confidence: 99%

Comparison between the effects of inhaled isoprenaline and fenoterol on plasma cyclic AMP and heart rate in normal subjects.

Fairfax¹,

Rehahn²,

Jones³

et al. 1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 The time course of changes in plasma cyclic AMP, heart rate and bronchial tone after inhalation of fenoterol or isoprenaline from a dose-metered aerosol are reported in a group of normal subjects. 2 After isoprenaline, plasma cyclic AMP increased rapidly reaching a peak by 10 min and returned to basal levels within 60 min. A rapid, transient rise in heart rate occurred that was maximal by 5 min and returned to a basal level by 45 min. 3 After fenoterol, the changes in cyclic AMP and heart rate were of much longer duration. The rise in plasma cyclic AMP was slower in onset and of greater magnitude than for isoprenaline, reaching a peak by 20 min and remaining above basal level for more than 6 h. The maximum increase in heart rate after fenoterol was less than that observed with isoprenaline but an elevated rate persisted for 4 h after inhalation of fenoterol. 4 Fenoterol is known to have a longer duration of action as a bronchodilator in comparison with isoprenaline. The prolonged rise in plasma cyclic AMP in normal subjects given inhaled fenoterol may reflect this long duration of action. The concomitant rise in heart rate, however, suggests that the duration of plasma cyclic AMP response may in part be due to the systemic effect of the fraction of inhaled fenoterol known to be absorbed via the buccal and intestinal routes.

show abstract

“…Da die NO-Bildung eine cGMP-Produktion auslöst, kann die cGMP-Bestimmung als Mass für die NO-Produktion herangezogen werden [8]. Obwohl dieser Prozess intrazellulär stattfindet, erlaubt eine Erfassung des extrazellulär auftretenden cGMP, Rückschlüsse auf die Beeinflussbarkeit des NO-cGMP-Systems zu ziehen [9,10]. In der vorliegenden Arbeit konnte weder nach oraler noch nach transdermaler Östradiolzufuhr eine signifikante Veränderung der cGMP-Produktion festgestellt werden.…”

Section: Patientinnen Und Methodikunclassified

Wirkung von transdermaler oder oraler Östradiolgabe auf die Ausscheidung vasoaktiver Mediatoren bei postmenopausalen Frauen

Mueck¹,

Seeger²,

Th³

2000

Gynäkol Geburtshilfliche Rundsch

View full text Add to dashboard Cite

Fragestellung: Wirken die transdermale (n = 20) und die orale (n = 20) Östradiolsubstitution auf die renale Ausscheidung von vasoaktiven Substanzen bei postmenopausalen Frauen? Methode: Als vasoaktive Substanzen wurden Prostazyklin und Thromboxan, zyklisches Guanosinmonophosphat, das die systemische Stickstoffmonoxidproduktion reflektieren kann, Serotonin, Relaxin, Insulin und Melatonin im 8-Stunden-Nachturin vor und nach 2- und 4wöchiger Östradiolbehandlung bestimmt. Ergebnisse: Die Ausscheidung von Prostazyklin und Thromboxan wurde, als Prostazyklin/Thromboxan-Quotient berechnet, durch beide Anwendungsformen zugunsten der Prostazyklinproduktion erhöht. Für die Ausscheidung von zyklischem Guanosinmonophosphat wurden nur geringgradige Veränderungen beobachtet. Die Produktion von Serotonin, Relaxin und Insulin wurde nur unter transdermaler Behandlung gesteigert. Für Melatonin wurden keine Veränderungen registriert. Schlussfolgerungen: Die hormonelle Substitutionstherapie mit Östradiol bei postmenopausalen Frauen kann, sowohl bei transdermaler als auch bei oraler Gabe, die Ausscheidung verschiedener vasoaktiver Substanzen erhöhen, welche auf vasorelaxierende Östrogenwirkungen hinweisen. Durch die transdermale Applikation wurde dabei eine höhere Wirksamkeit erzielt, obwohl wesentlich geringere Dosen verabreicht wurden. Möglicherweise lässt sich dies durch die bei transdermaler Applikation erfolgende kontinuierliche Einwirkung auf die östrogenen Endorgane erklären.

show abstract

Extracellular Cyclic Nucleotides*

Cited by 105 publications

References 56 publications

Sources of Cyclic Nucleotides in Plasma

Sources of Cyclic Nucleotides in Plasma

Comparison between the effects of inhaled isoprenaline and fenoterol on plasma cyclic AMP and heart rate in normal subjects.

Wirkung von transdermaler oder oraler Östradiolgabe auf die Ausscheidung vasoaktiver Mediatoren bei postmenopausalen Frauen

Contact Info

Product

Resources

About